A zithromycin dihydrate is an azalide antibiotic, a subclass of the macrolide antibiotics. The compatibility of azithromycin with other drugs during Y-site injection has not heretofore been studied.

Azithromycin is a versatile antibiotic used to treat a wide variety of bacterial infections, including those affecting the lungs, skin, and gastrointestinal system, as well as a number of sexually ...

Azithromycin dosages included the usual dose (250 mg to 500 mg orally once per day ... if any. While some drugs pose minor interaction risks, others may contraindicate use. A typical course ...

It is important to emphasize that this was a study of visual compatibility of drugs administered by simulated ... Amikacin VHA Plus 112180 1000 mg (100 mg/mL) in 0.45% sodium chloride injection ...

Recent research in clinical microbiology has highlighted the growing challenges posed by antibiotic resistance ... treatment options and to design new drugs that are less likely to encounter ...

A typical course of azithromycin runs for three to 10 days, depending on the type of infection being treated. The most common dosage on day one is 500 milligrams (mg) in a single dose, which might ...

Drugmaker Wockhardt has got off to an optimistic start this year with its novel antibiotic nafithromycin (Miqnaf) getting regulatory approval from the Central Drugs Standard Control Organization.

Central Drugs Standard Control Organization (CDSCO) approved antibiotic Nafithromycin ... Wockhardt claims current oral antibiotics such as azithromycin 'face significant resistance challenges ...

"Rather than identifying a novel drug candidate to treat these antibiotic ... azithromycin. As such, the researchers believe that their study opens the door to new clinical utility for old drugs ...

Aurelio Rojas Sánchez, who practices in Malaga, Spain, pinpointed three specific drugs that could potentially ... on whether you need them or not. Antibiotic resistance is a big problem ...

there has been a lack of investment to develop new drugs for gonorrhoea,” commented Dr Manica Balasegaram, executive director of GARDP, which has rights to the novel antibiotic in around 130 ...

In India, antibiotic resistance is a burning issue, including in community pneumonia cases. A key strength of Miqnaf is its ability to target a wide range of respiratory infections, including bacteria ...